iBio and AstralBio, two biotechnology companies based in the US, have discovered an antibody which can reportedly be used in the treatment of obesity and cardiometabolic disorders as part of an ongoing collaboration.

An agreement between the two companies permits AstralBio with an exclusive licence to iBio’s Drug Discovery Platform. This enables AstralBio to engineer four targets for treating cardiometabolic disease, along with the option to continue preclinical development. In turn, iBio has the exclusive right to license three cardiometabolic targets from AstralBio and will then receive rights in order to manufacture, develop and commercialise said targets.